Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (1)
  • Allergy asthma and a sport (3)
  • Allied health and primary care (8)
  • Anaphylaxis (2)
  • Artificial Intelligence (1)
  • Asthma (13)
  • x Biologicals (3)
  • Drug allergy (1)
  • ENT (1)
  • Environmental allergy and climate change (2)
  • Epidemiology (3)
  • Food allergy (3)
  • Genomics and proteomics (1)
  • Immune deficiencies and autoimmunity (1)
  • Infections (1)
  • Occupational allergy (2)
  • Pediatrics (3)
  • Prevention (3)
Poster available until
Poster categories
  • Thematic Poster Session (3)
keywords
Session Reference
  • L-TPS02 (9)
  • L-TPS07 (11)
  • L-TPS08 (1)
  • L-TPS09 (3)
  • x L-TPS10 (1)
  • L-TPS19 (1)
  • L-TPS21 (1)
  • TPS06 (8)
  • TPS09 (2)
  • TPS17 (4)
  • TPS18 (9)
  • TPS29 (1)
  • TPS51 (1)
  • TPS52 (5)
  • TPS55 (10)
  • TPS56 (5)
  • TPS57 (1)
  • TPS63 (1)
  • TPS67 (9)
  • x TPS69 (2)
3 results
Thumbnail

D2.147 - Comparison of clinical outcomes with Benralizumab in severe eosinophilic asthma: Switched and naïve patients

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM